Blogs

electroCore Expands Intellectual Property Portfolio

Forex

<p>electroCore Granted Two New U.S. Patents ROCKAWAY, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO). The two patents were is

Talonvest Capital Closes Financing for Georgia Portfolio

Forex

<p>Castle Hill Investors Self storage facility in Georgia IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) &#8212; Talonvest Capital, Inc., a boutique self-storage and commercial real estate advisory firm, along with their client Castle Hill Investors LLC, are thrilled to announce the successful closing of a $25,250,000 loan for the refinan

Bionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and Karyotyping

Forex

<p>Key findings from prospective evaluation of 200 prenatal samples: Optical genome mapping (OGM) detected pathogenic structural variants (SVs) in 20.5% of samples (41/200); combination of chromosomal microarray analysis (CMA) and karyotyping (KT) detected pathogenic SVs in 19.5% of samples (39/200) Compared to CMA and KT combined in this pro

Inspired Announces CFO Transition

Forex

<p>NEW YORK, Dec. 26, 2023 (GLOBE NEWSWIRE) — Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, today announced that Marilyn Jentzen has been appointed Interim CFO and principal accounting officer, upon the Company’s acceptance of Stewa

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

Forex

<p> Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma’s double-blind, placebo-controlled study to investigate tafenoquine for treatment of hospitalized babesiosis patients The previously announced Type C meeting with FDA has been rescheduled by FDA from January 15 to January 17, 2024, due to a federal holiday

Page 1040 of 9786